• Second consecutive quarter of positive cash flows from operations
• Total revenue guidance maintained at NZ$76-79 million on constant currency basis
• Normalised EBITDA guidance maintained at NZ$0-2 million

Aroa Biosurgery Limited (ASX: ARX) has reported its financial and operational results for the quarter ended 31 March 2025. The company posted its second consecutive quarter of positive cash flows from operations, with NZ$1.1 million in cash flow from operations for the quarter. Total cash on hand increased by NZ$0.1 million, ending the quarter with a strong cash balance of NZ$22.0 million. The company reported strong cash receipts from customers of NZ$20.1 million for the quarter, in line with expectations. Net cash outflow from investing activities was NZ$0.6 million for the quarter, primarily reflecting routine capital expenditure. Aroa maintained its full-year FY25 guidance of NZ$76-79 million in total revenue on a constant currency basis and a normalised EBITDA profit of NZ$0-2 million. On a reported currency basis, the company's full-year FY25 guidance is NZ$81-84 million in total revenue and a normalised EBITDA profit of NZ$2-4 million. Operationally, the company reported record sales of its Myriad product in March 2025 of US$2 million, an 11% increase on the prior quarter and 32% against the prior corresponding period. Demand for the company's Ovitex product also remained strong, with sales to TelaBio increasing by 17% compared to the previous corresponding period. Aroa continues to build its clinical evidence, with over 100 peer-reviewed studies now published validating its AROA ECM technology platform. The company also appointed its first US-based Marketing Director, Ruth Powers, to drive market growth and build further sales momentum.

Aroa maintains its full-year FY25 guidance of NZ$76-79 million in total revenue on a constant currency basis and a normalised EBITDA profit of NZ$0-2 million. On a reported currency basis, the company's full-year FY25 guidance is NZ$81-84 million in total revenue and a normalised EBITDA profit of NZ$2-4 million.

Aroa has made pleasing progress in Q4, demonstrated by its second consecutive quarter of positive operating cash flows and record sales of Myriad in March 2025. With a strong cash balance, the company is well positioned to continue to invest in growing both topline and EBITDA.